EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Evaluating the Effectiveness of NOACs and LMWH in Reducing Mortality in Critically Ill Patients With COVID‐19

Rubens Carmo Costa-Filho iD, Amarino Oliveira iD, Felipe Saddy iD, João Luiz Ferreira Costa iD, Marcela Santos Azevedo iD, Débora Fragoso Cerqueira iD, Víctor Hugo Amaral Gualberto iD, Maria Izabel Neves de Holanda Barbosa iD, Alda Maria Da-Cruz iD, Marco Aurélio Horta iD, José Paulo Gagliardi Leite iD, Hugo Castro-Faria-Neto iD

Journal of Medical Virology · 2025

DOI: 10.1002/jmv.70535 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Medical Virology, 2025. Verfasst von Rubens Carmo Costa-Filho und 11 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Immunopharmacology - IOC/FIOCRUZ, Rio de Janeiro, RJ, Brazil. Hauptthemen laut MEDLINE: Heparin, Low-Molecular-Weight, Anticoagulants, COVID-19, COVID-19 Drug Treatment. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The study was supported by the Conselho Nacional de Desenvolvimento Científico e Tecnológico and Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Severe COVID‐19 is associated with increased prothrombotic and inflammatory responses, necessitating effective anticoagulation therapy. Novel oral anticoagulants (NOACs) are being explored as potential alternatives to low‐molecular‐weight heparin (LMWH). This retrospective observational cohort study compared the effectiveness and safety of NOACs and LMWH in reducing mortality among 76 critically ill, unvaccinated patients with confirmed SARS‐CoV‐2 infection. The cohort included 41 patients treated with LMWH and 35 with NOACs during their ICU stay. The primary outcomes was mortality, while secondary outcomes included deep vein thrombosis (DVT), bleeding episodes, and transfusion rates. Baseline characteristics, including demographic data and severity scores, were similar between the groups (mean age: LMWH, 74.5 ± 15.1 years [59% male]; NOAC, 71.6 ± 14.8 years [60% male]). Mortality was significantly higher in the LMWH group (51.21% [95% confidence interval (CI): 36.4–65.7]) compared to the NOAC group (20% [95% CI: 10.0–35.9]; p = 0.005), with standardized mortality ratios of 1.61 and 0.71, respectively ( p = 0.004). Elevated d ‐dimer levels were strongly associated with an increased risk of mortality. Deep vein thrombosis (DVT) occurred in 9.76% of patients in the LMWH group and 5.71% of those in the NOAC group ( p = 0.68). Bleeding and transfusion rates were comparable between the groups. The use of NOACs was associated with a significantly lower mortality rate compared to LMWH in critically ill COVID‐19 patients, reflecting an 81% reduction in the risk of death. These findings highlight the potential benefits of NOACs in the management of severe COVID‐19 and underscore the need for further research to optimize anticoagulation strategies and improve patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heparin, Low-Molecular-WeightAnticoagulantsCOVID-19COVID-19 Drug TreatmentHumansMaleFemaleAgedRetrospective StudiesCritical IllnessMiddle AgedAged, 80 and overHemorrhageVenous ThrombosisTreatment OutcomeSARS-CoV-2Administration, Oral

Stichwörter der Autor:innen

COVID‐19anticoagulationcoagulopathyd‐dimerthrombosis

Substanzen

Heparin, Low-Molecular-WeightAnticoagulants

Autor:innen und Institutionen

  • Laboratory of Immunopharmacology - IOC/FIOCRUZ, Rio de Janeiro, RJ, Brazil.
  • Intensive Care Unit, Hospital Pró-Cardíaco, Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
  • Faculdade de Medicina, Universidade Estácio de Sá, IDOMED, Rio de Janeiro, RJ, Brazil.
  • Department of Radiology, Hospital Pró-Cardíaco, Rio de Janeiro, RJ, Brazil.
  • Nephrology Department, Hospital Pró-Cardíaco, Rio de Janeiro, RJ, Brazil.
  • Department of Parasitology/DMIP, Interdisciplinary Laboratory of Medical Research, IOC/FIOCRUZ, Faculty of Medical Sciences, UERJ, Rio de Janeiro, RJ, Brazil.

ORCID-Profile: Rubens Carmo Costa-Filho, Amarino Oliveira, Felipe Saddy, João Luiz Ferreira Costa, Marcela Santos Azevedo, Débora Fragoso Cerqueira, Víctor Hugo Amaral Gualberto, Maria Izabel Neves de Holanda Barbosa, Alda Maria Da-Cruz, Marco Aurélio Horta, José Paulo Gagliardi Leite, Hugo Castro-Faria-Neto

Förderung

  • The study was supported by the Conselho Nacional de Desenvolvimento Científico e Tecnológico and Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do…

Zitieren

APA

Costa-Filho, R. C., Oliveira, A., Saddy, F., Costa, J. L. F., Azevedo, M. S., Cerqueira, D. F., Gualberto, V. H. A., Barbosa, M. I. N. H., Da-Cruz, A. M., Horta, M. A., Leite, J. P. G., & Castro-Faria-Neto, H. (2025). Evaluating the Effectiveness of NOACs and LMWH in Reducing Mortality in Critically Ill Patients With COVID‐19. Journal of Medical Virology. https://doi.org/10.1002/jmv.70535

Vancouver

Costa-Filho RC, Oliveira A, Saddy F, Costa JLF, Azevedo MS, Cerqueira DF, et al. Evaluating the Effectiveness of NOACs and LMWH in Reducing Mortality in Critically Ill Patients With COVID‐19. Journal of Medical Virology. 2025. doi:10.1002/jmv.70535

BibTeX
@article{CostaFilho2025,
  author = {Costa-Filho, Rubens Carmo and Oliveira, Amarino and Saddy, Felipe and Costa, João Luiz Ferreira and Azevedo, Marcela Santos and Cerqueira, Débora Fragoso and Gualberto, Víctor Hugo Amaral and Barbosa, Maria Izabel Neves de Holanda and Da-Cruz, Alda Maria and Horta, Marco Aurélio and Leite, José Paulo Gagliardi and Castro-Faria-Neto, Hugo},
  title = {Evaluating the Effectiveness of NOACs and LMWH in Reducing Mortality in Critically Ill Patients With COVID‐19},
  journal = {Journal of Medical Virology},
  year = {2025},
  doi = {10.1002/jmv.70535}
}
Kostenlos starten →